EPLR Journal

+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Issue 3/18 of EPLR - European Pharmaceutical Law Review

Policy makers and courts tend to slow down their output during the summer, and this is no different for those working in the pharmaceutical community. With EMA focused on moving their headquarters to Amsterdam in the wake of Brexit, this trend is particularly pronounced. However, this does not mean that there were no legal and regulatory developments which merit our attention. Indeed, issue 3/2018 of EPLR features two articles on core regulatory challenges in the pharmaceuticals field: allegations of excessive pharmaceutical pricing and the contentious topic of off label use.

In addition, we have also included reports from Germany and the United Kingdom and a topical report on biosimilar authorisation. The issue concludes with a timely Case Note by Minssen and Bostyn who criticise the Court of Justice for failing to clearly determine ‘when a product is protected by a basic patent’. Please have a look at the latest issue: here.

Are you interested in contributing to the journal? View our Call for Papers.

Stay posted and sign up for our newsletter!
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +

Publication frequency: quarterly
approx. 70 pages
ISSN: 2511-7157

Annual subscription
Special Offer

 

European Pharmaceutical Law Review - EPLR

The European Pharmaceutical Law Review (EPLR) identifies and analyses important legal and regulatory developments on the national, EU and international level. Furthermore, it provides an overview of and critically examines judgments that shape the interpretation and application of EU pharmaceutical law and policy, in particular those by the European Courts, international courts and tribunals such as the WTO's Dispute Settlement Body, and higher national courts.

In order to establish itself as a forum for dialogue between different stakeholders in pharmaceutical regulation and governance, EPLR invites contributions from academics, practitioners, regulators and civil society representatives.

Topics covered by EPLR include:

  • pharmaceutical law and policy in all jurisdictions (regional, national, international);
  • Commission decisions (EMA opinions) and regulatory guidelines;
  • national, EU, and international jurisprudence;
  • medical devices;
  • borderline cases: pharmaceuticals/food/cosmetics/chemicals
  • patents /trademarks;
  • health technology assessment and pricing/reimbursement;
  • digital health/big data;
All contributions will be subject to double blind peer-review before acceptance for publication and are required to conform to the author guidelines.

EPLR's Target Audience

The quarterly journal addresses everyone who is concerned with pharmaceutical law and policy issues such as academics (in the field of law, pharmacy and medicine, regulatory science, and other relevant research fields), legal practitioners in national and international law firms, regulators such government officials working in EU  and national public administration, judges and legal experts in domestic, European and international courts, consultancies, business people in the EU and beyond as well as stakeholder organisations representing professionals, patients, and civil society.

EPLR's Structure

Each issue of EPLR will be a balanced mixture of original research articles, first-hand country or thematic policy reports, timely case annotations on important ECJ/GC rulings and other international/national court judgments, book reviews as well as other information material and updates, including opinions, case summaries or event reports.

 

 

Managing Editor

Sabrina Röttger-Wirtz
Tilburg University

Reports Editor

Eveline Van Keymeulen
Allen & Overy

Editorial Board



Ulrich M. Gassner
University of Augsburg

Richard S. Goldberg
Durham University

Leigh Hancher
University of Tilburg / Allen & Overy

Isabelle Huys
KU Leuven

Trudo Lemmens
University of Toronto

Robert Madelin
Foresight International Policy and Regulatory Advisers

Timo Minssen
University of Copenhagen

George Peretz
Monckton Chambers

Vincenzo Salvatore
University of Insubria/BonelliErede

Claudia Seitz
University of Basel

Alessandro Spina
European Medicines Agency

Karin Verzijden
Axon Lawyers

 
 
 

EXECUTIVE EDITOR

0 JMcK Photo Jakob McKernan
Tel.: +49 30-81 45 06-10
mckernan@lexxion.eu

CUSTOMER SERVICE

  (orders, enquiries, returns)

 CG

Cristina Gîrloanƫă
Tel.: +49 30-81 45 06-12
mail@lexxion.eu



mckernan@lexxion.eu

EStAL
Journal
Publication frequency: quarterly
Subscription: € 442,-
ISSN 16 19-52 72

Further information

Media Partners

 

FORUMInstitut Banner EPLR Image 300x110px

 

This website uses Google Analytics for internal evaluation purposes. To prevent Google’s collection and use of data: click this link. An opt-out-cookie will be implemented. Please find more information in our data privacy information